GlassScriptPhysician profile
Casey J Boyles
NPI 1669459921
$8,107.72
in general payments reported to CMS, 2019-2025
52 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,944 · 2020: $551 · 2021: $608 · 2022: $908 · 2023: $1,174 · 2024: $1,475 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,096.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,001.50 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $948.01 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $861.57 | 2019-2025 | |
| Novo Nordisk INC | $683.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $500.17 | 2019-2025 | Repatha, Otezla, Evenity |
| Allergan, INC. | $333.01 | 2019-2020 | |
| Lilly USA, LLC | $277.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $222.01 | 2019-2024 | Shingrix, Trelegy Ellipta, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.80 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $214.87 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $213.73 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $210.88 | 2019-2021 | |
| Astellas Pharma US INC | $198.54 | 2019-2024 | Veozah |
| Abbott Laboratories | $177.63 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.13 | 2019-2023 | Trulance, Xifaxan |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Boyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.